AnaptysBio Ownership
| ANAB Stock | USD 15.51 7.58 32.83% |
Shares in Circulation | First Issued 2014-09-30 | Previous Quarter 27.4 M | Current Value 28.9 M | Avarage Shares Outstanding 35.7 M | Quarterly Volatility 26.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
AnaptysBio |
AnaptysBio Stock Ownership Analysis
About 98.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 6.05. AnaptysBio had not issued any dividends in recent years. AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. Anaptysbio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people. For more info on AnaptysBio please contact the company at 858 362 6295 or go to https://www.anaptysbio.com.Besides selling stocks to institutional investors, AnaptysBio also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different AnaptysBio's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align AnaptysBio's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
AnaptysBio Quarterly Liabilities And Stockholders Equity |
|
AnaptysBio Insider Trades History
Only 1.73% of AnaptysBio are currently held by insiders. Unlike AnaptysBio's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against AnaptysBio's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of AnaptysBio's insider trades
AnaptysBio Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AnaptysBio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AnaptysBio backward and forwards among themselves. AnaptysBio's institutional investor refers to the entity that pools money to purchase AnaptysBio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Assenagon Asset Management Sa | 2024-09-30 | 475.4 K | Geode Capital Management, Llc | 2024-09-30 | 465.4 K | Woodline Partners Lp | 2024-09-30 | 460 K | 5am Venture Management, Llc | 2024-09-30 | 357.7 K | Franklin Resources Inc | 2024-09-30 | 354.4 K | Goldman Sachs Group Inc | 2024-09-30 | 350.4 K | Cormorant Asset Management, Llc | 2024-09-30 | 342.5 K | Millennium Management Llc | 2024-09-30 | 331.6 K | Federated Hermes Inc | 2024-09-30 | 317.2 K | Ecor1 Capital, Llc | 2024-09-30 | 7.8 M | Fmr Inc | 2024-09-30 | 3.3 M |
AnaptysBio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AnaptysBio insiders, such as employees or executives, is commonly permitted as long as it does not rely on AnaptysBio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AnaptysBio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
AnaptysBio Outstanding Bonds
AnaptysBio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AnaptysBio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most AnaptysBio bonds can be classified according to their maturity, which is the date when AnaptysBio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
AnaptysBio Corporate Filings
8K | 11th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 3rd of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 15th of November 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.05) | Revenue Per Share 2.086 | Quarterly Revenue Growth 8.047 | Return On Assets (0.18) | Return On Equity (1.62) |
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.